Linazone-M – 2.5/500 Tablets – Linagliptin 2.5mg Metformin 500mg Tablets Manufacturer, Supplier, Franchise In India

Linazone-M 2.5/500 Tablets are a combination oral antidiabetic medication used for the effective management of type 2 diabetes mellitus. This formulation combines Linagliptin 2.5 mg, a DPP-4 inhibitor, with Metformin 500 mg, a biguanide, to provide dual-mechanism blood glucose control. It is especially beneficial for patients who require better glycemic control than what monotherapy can offer.

Type 2 diabetes involves multiple metabolic defects, including insulin resistance and impaired insulin secretion. Linazone-M addresses these issues simultaneously. Metformin improves insulin sensitivity and reduces glucose production in the liver, while Linagliptin enhances incretin hormone activity to increase insulin release and suppress excess glucagon. This complementary action results in effective and balanced blood sugar control with a low risk of hypoglycemia.

Mechanism of Action

• Linagliptin 2.5 mg inhibits the DPP-4 enzyme, increasing levels of active incretin hormones (GLP-1 and GIP), which stimulate glucose-dependent insulin secretion and reduce glucagon levels.

• Metformin 500 mg decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.

Together, these mechanisms help control both fasting and post-meal blood glucose levels.

Key Benefits of Linagliptin 2.5mg Metformin 500mg Tablets

Dual-action blood glucose control
Effective reduction of fasting and postprandial glucose levels
Low risk of hypoglycemia when used appropriately
Weight-neutral to weight-friendly profile
Suitable for long-term use
Convenient fixed-dose combination improves patient compliance